Skip to main content
. 2014 Apr 4;120(13):2006–2015. doi: 10.1002/cncr.28696

Figure 6.

Figure 6

Retrospective TumorGraft testing is illustrated. (A) Retrospective TumorGraft testing for patient POS-1009 reveals significant growth reduction with a combination of gemcitabine and docetaxel. (B,C) Retrospective TumorGraft testing for patient POS-1152 indicates strong antitumor effects with either trabectidin or ifosfamide. (D) Retrospective TumorGraft testing for patient POS-1255 demonstrates that, although eribulin and sunitinib slow tumor growth relative to controls, the patient's tumor still grows, albeit more slowly. Asterisks denote significance (a single asterisk indicates P ≤ .05; double asterisks, P ≤ .01; triple asterisks, P ≤ .001).